Sumitomo Pharma America
55 Cambridge Parkway Suite 102W
Cambridge, MA 02142
United States
Tel: +1(508)481-6700
Website: https://www.us.sumitomo-pharma.com/
About Sumitomo Pharma America
Focus Areas
We tackle unmet patient needs in the crucial fields of psychiatry and neurology, oncology, urology, women's health, rare diseases, and cell and gene therapies.
Technology
We unlock innovative science and solutions through cutting-edge technology. Advanced in-house technology platforms and data analytics capabilities de-risk and optimize clinical and commercial programs to accelerate insights in science, research, and discovery.
Advocating for Patients
We reimagine what’s possible We see people as more than the conditions they are managing. We are unwavering in our promise to advocate for patients and their families on the things that matter most to them. This promise is central to everything we do as we pursue unprecedented medical innovation.
Heritage
We are building on a legacy With Sumitomo Pharma's 125-year legacy as our foundation, Sumitomo Pharma America was formed through the consolidation of Sumitomo Pharma’s US affiliates. Our parent company, the Sumitomo Group, is over 400 years old, with an extensive history of supporting health and wellbeing.
CONNECT
166 articles about Sumitomo Pharma America
-
Myovant Initiates Phase III Clinical Trial Of Relugolix In Men With Advanced Prostate Cancer
3/2/2017
-
Myovant Release: Initiates Phase 3 Clinical Program Of Relugolix In Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
1/25/2017
-
Myovant Appoints Terrie Curran To Board Of Directors
11/16/2016
-
Myovant Announces Pricing Of Initial Public Offering
10/27/2016
-
Myovant Announces Appointment Of Board Of Directors
10/12/2016
-
Myovant Files for $172.5 Million IPO
10/3/2016